A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00429143
Recruitment Status : Completed
First Posted : January 31, 2007
Results First Posted : May 31, 2013
Last Update Posted : November 29, 2016
Information provided by (Responsible Party):
Thomas Jefferson University ( Sidney Kimmel Cancer Center at Thomas Jefferson University )

January 29, 2007
January 31, 2007
June 4, 2012
May 31, 2013
November 29, 2016
January 2006
August 2009   (Final data collection date for primary outcome measure)
  • Overall Survival of Participants [ Time Frame: 6 months ]
    To determine overall survival at 6 months post-transplant.
  • Optimal Dose of CD3+ Donor Lymphocytes (T-cells) for Consistent Engraftment Without GVHD [ Time Frame: 6 months ]
    To determine the optimal dose of CD3+ donor lymphocytes required for consistent engraftment without the development of grade III/IV GVHD. Measured as CD3+ donor lymphocytes given as n x 10^8/kg. "n" was found to be 2 and was found to be the optimal dose and was the only dose given.
Not Provided
Complete list of historical versions of study NCT00429143 on Archive Site
  • Engraftment Rates [ Time Frame: 6 months ]
    To assess hematopoietic engraftment rates.
  • Lymphoid Recovery [ Time Frame: 6 months ]
    To assess the pace of lymphoid recovery in this patient population.
  • Incidence of Grades III-IV GVHD [ Time Frame: 6 months ]
    To determine the incidence and severity of GVHD in these patients using a combination of cyclophosphamide, tacrolimus and mycophenolate mofetil (MMF) as GVHD prophylaxis.' Severity was graded using CTCAE 3.0 (1=mild, 2=moderate, 3=severe, 4=life threatening/disabling, 5=death)
Not Provided
Not Provided
Not Provided
A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative
A Two Step Approach To Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies From HLA Partially-Matched Related Donors
The purpose of this study is to develop a way of treating patients who do not have a completely matched family donor or a readily available unrelated donor with bone marrow transplant by using a partially-matched family donor. Patients receiving this type of transplant will receive chemotherapy and/or radiation to treat their disease. They will also receive their donor's cells in 2 parts. During the first part, the donor's lymphocytes will be exposed to one of the chemotherapy agents to help the patient become tolerant to the lymphocytes. In the second part of the transplant, the patient will receive their donor's stem cells to help recover their peripheral blood counts and establish long-term engraftment. The hypothesis of this study is that in partially-matched allogeneic transplant, there is a defined number of donor T-cells that can be treated and given to the recipient to avoid post-transplant infection without causing severe graft-versus-host disease.
Haploidentical hematopoietic stem cell transplant is a life-saving therapy for patients who are without well matched donors. This type of therapy has been associated with poor outcomes in the past due to complications such as infection. The Jefferson 2 Step approach was designed to allow the infusion of an exact dose of tolerized lymphocytes in haploidentical transplant in order to allow for immune reconstitution post transplant to avoid infectious complications while still having acceptable rates of GVHD. In this approach, patients with high-risk hematological malignancies undergo 8 fractions of TBI (12 Gy) followed by an exact dose of donor lymphocytes. The phase I portion of the study determined the optimal dose of lymphocytes. Two days after receiving the donor lymphocytes, the patients receive 2 daily doses of cyclophosphamide. One day after receiving cyclophosphamide, the patients receive stem cell from their donor. Tacrolimus and mycophenylate mofetil are used as GVHD prophylaxis.
Phase 1
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Hematologic Malignancies
  • Radiation: Total Body Irradiation (TBI)
    TBI twice daily days 6-9 prior to transplant (HSCT)
    Other Names:
    • TBI
    • radiotherapy
  • Biological: Donor Lymphocyte Infusion (DLI)
    DLI given 6 days prior to transplant (HSCT).
    Other Names:
    • DLI
    • T cell infusion
  • Drug: Cyclophosphamide (CY)
    Cyclophosphamide given once daily at 60 mg/kg on days 2 and 3 prior to transplant (HSCT).
    Other Names:
    • CY
    • Endoxan
    • Cytoxan
    • Neosar
    • Procytox
    • Revimmune
    • cytophosphane
  • Drug: Tacrolimus
    Tacrolimus given one day prior to transplant (HSCT).
    Other Names:
    • FK-506
    • fujimycin
    • Prograf
    • Advagraf
    • Protopic
  • Drug: Mycophenolate Mofetil (MMF)
    MMF given one day prior to transplant (HSCT).
    Other Names:
    • MMF
    • CellCept
    • Myfortic
  • Biological: Hematopoietic Stem Cell Transplant (HSCT)
    CD34+ selected Hematopoietic Stem Cell Transplant (HSCT) is performed. This is the day of transplantation.
    Other Names:
    • HSCT
    • stem cell transplant
Experimental: Haploidentical Allogeneic Transplantation
Patients undergoing hematopoietic stem cell transplant from a partially matched related donor
  • Radiation: Total Body Irradiation (TBI)
  • Biological: Donor Lymphocyte Infusion (DLI)
  • Drug: Cyclophosphamide (CY)
  • Drug: Tacrolimus
  • Drug: Mycophenolate Mofetil (MMF)
  • Biological: Hematopoietic Stem Cell Transplant (HSCT)
Grosso D, Carabasi M, Filicko-O'Hara J, Kasner M, Wagner JL, Colombe B, Cornett Farley P, O'Hara W, Flomenberg P, Werner-Wasik M, Brunner J, Mookerjee B, Hyslop T, Weiss M, Flomenberg N. A 2-step approach to myeloablative haploidentical stem cell transplantation: a phase 1/2 trial performed with optimized T-cell dosing. Blood. 2011 Oct 27;118(17):4732-9. doi: 10.1182/blood-2011-07-365338. Epub 2011 Aug 25.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
June 2010
August 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Any patient with a hematologic or oncologic diagnosis in which allogeneic HSCT is thought to be beneficial, and in whom front-line therapy has already been applied.
  2. Patients must have a related donor who is either a one, two or three out of six antigen mismatch at the HLA-A;B;DR loci.
  3. Patients without a well-matched unrelated donor or those who have a disease status that precludes a wait for an identified unrelated donor.
  4. Patients must adequate organ function:

    • LVEF of >45%
    • FVC or FEV1 >45% of predicted
    • Adequate liver function as defined by a serum bilirubin <1.8, AST or ALT < 2.5X upper limit of normal
    • Serum creatinine < 2.0 mg/dl or creatinine clearance of > 40 ml/min
  5. Performance status > 60% (Karnofsky)
  6. Patients must be willing to use contraception if they have childbearing potential
  7. Able to give informed consent

Exclusion Criteria:

  1. An eligible HLA-identical sibling donor.
  2. Performance status < 60% (Karnosfsky)
  3. HIV positive
  4. Active involvement of the central nervous system with malignancy
  5. Psychiatric disorder that would preclude patients from signing an informed consent
  6. Pregnancy
  7. Patients with life expectancy of < 6 months for reasons other than their underlying hematologic/oncologic disorder.
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
United States
2005-84 ( Other Identifier: CCRRC )
Not Provided
Not Provided
Thomas Jefferson University ( Sidney Kimmel Cancer Center at Thomas Jefferson University )
Sidney Kimmel Cancer Center at Thomas Jefferson University
Not Provided
Principal Investigator: Neal Flomenberg, MD Thomas Jefferson University
Thomas Jefferson University
October 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP